Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2019 Mar;98(9):e14708.
doi: 10.1097/MD.0000000000014708.

Effectiveness and safety of Xuefu Zhuyu decoction for treating coronary heart disease angina: A systematic review and meta-analysis

Tao Yang  1 , Xiao Li  2 , Ziwen Lu  1 , Xiaowan Han  3 , Mingjing Zhao  1
Affiliations
Meta-Analysis

Effectiveness and safety of Xuefu Zhuyu decoction for treating coronary heart disease angina: A systematic review and meta-analysis

Tao Yang et al. Medicine (Baltimore). 2019 Mar.

Abstract

Background: Coronary heart disease angina is a very common cardiovascular disease, which not only causes personal health problems, but also a serious burden on the social economy. Xuefu Zhuyu Decoction (XFZYD) has been widely adapted to clinical practice for people with coronary heart disease angina. At present, it is necessary to update the existing research, re-evaluate the effectiveness and safety of XFZYD, and provide the latest evidence for coronary heart disease angina.

Methods and analysis: The purpose of this study was to search the electronic database for XFZYD in the treatment of coronary heart disease angina. The database includes PubMed, EMBASE, Cochrane Library, Chinese National Knowledge Infrastructure database (CNKI), Wanfang database, Chinese Biomedical Literature database (CBM), Chinese Scientific Journal database (VIP). In addition, ongoing trials will be retrieved from the WHO ICTRP Search Portal, the Chinese Clinical Trial Register and The Clinical Trials Register. We will assess all the documents from the database establishment to January 31, 2019. The RevMan V.5.3 software will be used to calculate the data synthesis and perform a meta-analysis when the literature is appropriate.

Results: The study will provide a high-quality synthesis of current evidence of XFZYD for coronary heart disease angina from the various comprehensive assessment, including Significantly effective, Effective, Invalid, Aggravation, which based on the "Guidelines for Clinical Research of New Chinese Medicine". Adverse events are also included.

Conclusion: The systematic review will provide evidence for assessing the effectiveness and safety of XFZYD in the treatment of coronary heart disease angina.

Prospero registration number: PROSPERO CRD42019122003.

PubMed Disclaimer

Conflict of interest statement

The authors have no conflicts of interest in this work.

Figures

Figure 1
Figure 1
The PRISMA flow chart.
Figure 2
Figure 2
Flow diagram of the systematic review and meta-analysis.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Geneva World Health Organization, Mendis S, Puska P, Norrving B, et al. Global atlas on cardiovascular disease prevention and control. 2011.
    1. Di Cesare M, Khang YH, Asaria P, et al. Inequalities in non-communicable diseases and effective responses. Lancet 2013;381:585–97. - PubMed
    1. Mortality GBD, Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet 2016;388:1459–544. - PMC - PubMed
    1. Elsevier Health Sciences, Dorland WAN. Dorland's Illustrated Medical Dictionary32: Dorland's Illustrated Medical Dictionary. 2011.
    1. Williams H. Angina: management options. Lung Cancer 2018;15:5.

MeSH terms

Substances